APLT News and Press, Applied Therapeutics Inc. From 04/27/23

2023-04-27 11:12:14 ET Numerous factors must be considered as you search for penny stocks to buy in the current market. Emotions are running high, from overarching recession and inflation narratives to the potential for a stock market crash in 2023. This has led to increased volatility ...

2023-04-25 11:28:44 ET Numerous factors in the current stock market must be considered as you search for penny stocks to invest in. Emotions are running high between the broad economic concerns of recession and inflation or the potential for a stock market crash in 2023. This heightened...

2023-04-24 08:09:23 ET Applied Therapeutics ( NASDAQ: APLT ) enters securities purchase agreement for the sale of 9.74M shares at a purchase price of $0.946 per share and 22M pre-funded warrants. Gross proceeds of ~$30M are expected. Closing is expected ...

Govorestat demonstrated consistent long-term clinical outcomes benefit across a range of functional measures in the ACTION-Galactosemia Kids trial, confirming prior biomarker data Govorestat treatment improved activities of daily living, behavior, cognition, fine motor skills, adaptive skills...

NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today anno...

2023-03-23 09:08:13 ET Applied Therapeutics press release ( NASDAQ: APLT ): FY GAAP EPS of -$2.18 beats by $0.44 . Cash and cash equivalents and short-term investments totaled $30.6 million as of December 31, 2022, compared with $80.8 million at December 31, 2021. ...

Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, Including Positive Sorbitol Reduction Data from the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency On Track to Report Additional Phase 3 Data Across Multiple Programs in 2023 NEW YORK...

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate...

Applied Therapeutics ( NASDAQ: APLT ) reported data from an ongoing phase 3 trial of oral AT-007 in 50 patients aged 16 years to 55 years with Sorbitol Dehydrogenase (SORD) Deficiency. An interim analysis of the study, dubbed INSPIRE, showed that AT-007 reduced sorbitol leve...

The ongoing Phase 3 INSPIRE trial is evaluating the effect of AT-007 vs. placebo in patients with SORD Deficiency on sorbitol reduction as well as clinical outcomes in approximately 50 patients age 16-55 in the US and Europe AT-007 reduced sorbitol by a mean of 52%, or approximately 16,00...